Orexigen Therapeutics, Inc. (OREX)
-NasdaqGS 6.04 
0.01(0.17%) May 17, 4:00PM EDT|After Hours
:
6.05 0.01 (0.17%) May 17, 7:41PM EDT
| Prev Close: | 6.05 |
|---|
| Open: | 6.10 |
|---|
| Bid: | 5.83 x 100 |
|---|
| Ask: | 7.16 x 1000 |
|---|
| 1y Target Est: | 10.57 |
|---|
| Beta: | 2.69 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 6.01 - 6.12 |
|---|
| 52wk Range: | 3.10 - 7.73 |
|---|
| Volume: | 688,839 |
|---|
| Avg Vol (3m): | 1,123,730 |
|---|
| Market Cap: | 571.64M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Orexigen Therapeutics to Present at the UBS Global Healthcare ConferencePR Newswire(Fri, May 17)
- Due Diligence in Finding the Value of Pharmaceuticals: Expert Portfolio Manager Finny Kuruvilla Discusses His Portfolio Construction Strategy with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- Orexigen Therapeutics' Management Presents at Bank of America Merrill Lynch Health Care Conference - Transcriptat Seeking Alpha(Wed, May 15)
- Weight Loss Isn't Just for Looking Good Anymoreat Motley Fool(Wed, May 15)
- OREXIGEN THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Wed, May 15)
- Will Obesity Drugs Gain Soon?at Motley Fool(Wed, May 15)
- Looking at Arena Following Sell-Offat Motley Fool(Tue, May 14)
- Vivus Starting To Gain The Advantage Over Arenaat Seeking Alpha(Tue, May 14)
- SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc.Business Wire(Mon, May 13)
- Why Does Arena's Obesity Drug Have Abuse Potential?at Forbes(Sat, May 11)
- Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care ConferencePR Newswire(Fri, May 10)
- ARNA Sheds Light on Belviq LaunchZacks(Thu, May 9)
- VIVUS Reports Wider LossZacks(Thu, May 9)
- OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Orexigen Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 167.03 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.79 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -0.51 |
|---|
Business Summary
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
View More